Vigil Neuroscience Inc. (VIGL)
Company Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases.
Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease.
The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction.
Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Country | United States |
IPO Date | Jan 7, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 69 |
CEO | Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. |
Contact Details
Address: 1 Broadway Cambridge, Massachusetts United States | |
Website | https://www.vigilneuro.com |
Stock Details
Ticker Symbol | VIGL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001827087 |
CUSIP Number | 92673K108 |
ISIN Number | US92673K1088 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, Chief Executive Officer & Director |
Charles J. Democko | Senior Vice President, Regulatory Affairs & Quality |
Kevin Durfee | Vice President & Head of Information Technology |
Ommer Chohan | Secretary |
Sharon Morani | Senior Director of Facilities & Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 31, 2025 | S-3 | Filing |
Mar 31, 2025 | ARS | Filing |
Mar 31, 2025 | DEFA14A | Filing |
Mar 31, 2025 | DEF 14A | Filing |
Mar 13, 2025 | S-8 | Filing |
Mar 13, 2025 | 10-K | Annual Report |
Mar 13, 2025 | 8-K | Current Report |
Mar 04, 2025 | 4 | Filing |
Mar 04, 2025 | 4 | Filing |
Mar 04, 2025 | 4 | Filing |